CELLECTIS - ADR (CLLS) Stock Price, Forecast & Analysis
NASDAQ:CLLS • US15117K1034
CLLS Key Statistics, Chart & Performance
The current stock price of CLLS is 4.01 USD. In the past month the price decreased by -1.72%. In the past year, price increased by 206.98%.
CLLS Technical Analysis
ChartMill assigns a technical rating of 6 / 10 to CLLS. When comparing the yearly performance of all stocks, CLLS is one of the better performing stocks in the market, outperforming 96.05% of all stocks.
CLLS Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to CLLS. CLLS has a bad profitability rating. Also its financial health evaluation is rather negative.
CLLS Financial Highlights
Over the last trailing twelve months CLLS reported a non-GAAP Earnings per Share(EPS) of -0.33. The EPS increased by 70.8% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -28.25% | ||
| ROE | -102.97% | ||
| Debt/Equity | 0.91 |
CLLS Forecast & Estimates
13 analysts have analysed CLLS and the average price target is 7.71 USD. This implies a price increase of 92.26% is expected in the next year compared to the current price of 4.01.
For the next year, analysts expect an EPS growth of -166.15% and a revenue growth 45.52% for CLLS
CLLS Ownership
CLLS Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.73 | 405.578B | ||
| AMGN | AMGEN INC | 16.99 | 204.31B | ||
| GILD | GILEAD SCIENCES INC | 16.55 | 185.891B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.91 | 122.042B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.62 | 83.206B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 49.69 | 43.51B | ||
| INSM | INSMED INC | N/A | 33.916B | ||
| NTRA | NATERA INC | N/A | 29.129B | ||
| BIIB | BIOGEN INC | 12.83 | 28.815B | ||
| UTHR | UNITED THERAPEUTICS CORP | 16.06 | 20.433B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About CLLS
Company Profile
Cellectis SA operates as a clinical stage biotechnological company, which engages in gene-editing platform to develop cell and gene therapies. The company is headquartered in Paris, Ile-De-France and currently employs 224 full-time employees. The company went IPO on 2007-02-06. The firm specializes in the research, development, and commercialization of rational genome engineering technologies. The firm develops immunotherapies that aim to force the immune system to target and eradicate cancer cells. The company has developed an expertise in combining meganucleases with engineered targeting Deoxyribonucleic Acid (DNA) matrices into Meganuclease Recombination Systems (MRS), used for gene excision, correction or replacement. Cellectis SA markets its technologies mainly for use in the research field, in pharmaceutical drug discovery programs, in the agronomics, bioproduction, and biotherapeutics fields. Cellectis SA operates several subsidiaries. The firm operates in France and the United States, among others.
Company Info
CELLECTIS - ADR
8, rue de la Croix Jarry
Paris ILE-DE-FRANCE 75013 FR
CEO: Andre Choulika
Employees: 219
Phone: 33181691600
CELLECTIS - ADR / CLLS FAQ
What does CELLECTIS - ADR do?
Cellectis SA operates as a clinical stage biotechnological company, which engages in gene-editing platform to develop cell and gene therapies. The company is headquartered in Paris, Ile-De-France and currently employs 224 full-time employees. The company went IPO on 2007-02-06. The firm specializes in the research, development, and commercialization of rational genome engineering technologies. The firm develops immunotherapies that aim to force the immune system to target and eradicate cancer cells. The company has developed an expertise in combining meganucleases with engineered targeting Deoxyribonucleic Acid (DNA) matrices into Meganuclease Recombination Systems (MRS), used for gene excision, correction or replacement. Cellectis SA markets its technologies mainly for use in the research field, in pharmaceutical drug discovery programs, in the agronomics, bioproduction, and biotherapeutics fields. Cellectis SA operates several subsidiaries. The firm operates in France and the United States, among others.
Can you provide the latest stock price for CELLECTIS - ADR?
The current stock price of CLLS is 4.01 USD. The price increased by 1.26% in the last trading session.
Does CELLECTIS - ADR pay dividends?
CLLS does not pay a dividend.
What is the ChartMill technical and fundamental rating of CLLS stock?
CLLS has a ChartMill Technical rating of 6 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is the analyst forecast for CLLS stock?
13 analysts have analysed CLLS and the average price target is 7.71 USD. This implies a price increase of 92.26% is expected in the next year compared to the current price of 4.01.
Is CELLECTIS - ADR (CLLS) stock a good buy?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on CLLS.
Who owns CELLECTIS - ADR?
You can find the ownership structure of CELLECTIS - ADR (CLLS) on the Ownership tab.